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Patients with epilepsy and treated with antiepileptic drugs (AEDs) may develop metabolic
bone disease; however, the exact pathogenesis of bone loss with AEDs is still unclear.
Included were 75 adults with epilepsy (mean age: 31.90±5.62 years; duration of treatment
with AEDs: 10.57± 3.55 years) and 40 matched healthy controls. Bone mineral content
(BMC) and bone mineral densities (BMD) of the femoral neck and lumbar spine were
measured using dual-energy X-ray absorptiometry (DEXA). Blood samples were analyzed
for calcium, magnesium, phosphate, alkaline phosphatase (ALP), 25-hydroxy vitamin D
(25OHD), soluble receptor activator of nuclear factor-kappa B ligand (sRANKL), osteoprote-
gerin (OPG), and OPG/RANKL ratio (markers of bone remodeling). Compared to controls,
patients had lower BMD, BMC, Z -score, and T -score at the femoral neck and lumbar
spine (all p<0.001). Seventy-two percent and 29.33% of patients had osteoporosis of the
lumbar spine and femoral neck. Patients had significantly lower serum calcium, 25(OH)D,
and OPG and higher ALP, sRANKL levels, and sRANKL/OPG (all p<0.001). Fifty-two per-
cent of patients had hypocalcemia, 93% had hypovitaminosis D, 31% had high levels
of sRANKL, and 49% had low levels of OPG. No differences were identified between
DEXA and laboratory results in relation to the type, dose, or serum levels of AEDs. BMD
at the femoral neck and lumbar spine were found to be correlated with the duration
of illness (p=0.043; p=0.010), duration of treatment with AEDs (p<0.001; p=0.012),
and serum levels of 25(OH)D (p=0.042; p=0.010), sRANKLs (p=0.005; p=0.01), and
OPG (p=0.006; p=0.01). In linear regression analysis and after adjusting for gender,
age, weight, duration, and number of AEDs, we observed an association between BMD,
25(OH)D (p=0.04) and sRANKL (p=0.03) concentrations. We conclude that AEDs may
compromise bone health through disturbance of mineral metabolism and acceleration of
bone turnover mechanisms.
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INTRODUCTION
Epilepsy is one of the most common neurological disorders (1)
and its treatment is life-long in nearly one-third of the patients
(2). Several large epidemiological studies indicated that patients
with epilepsy are at two- to six-folds increase in the risk of fractures
compared to the general population (3). It has been reported that
more than 15% of fractures are pathological due to metabolic bone
disease (3, 4). Early reports suggested that institutionalization,
inadequate dietary intake with vitamin D deficiency/insufficiency,
reduced sunlight exposure (5), physical inactivity (6), aging (7),
and female sex (8) are risk factors for osteopathy with epilepsy.
However, many studies reported that antiepileptic drugs (AEDs)
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; AEDs, antiepileptic drugs; ALP,
alkaline phosphatase; BMC, bone mineral content; BMD, bone mineral density;
CBZ, carbamazepine; OPG, osteoprotegerin; sRANKL, soluble receptor activator of
nuclear factor-kappa B ligand; VPA, valproic acid.
are major risk factors for bone disease in non-institutionalized
patients and well-nourished ambulatory adults with epilepsy
(9–12). Early reports incriminated AEDs with enzyme induc-
tion activity or their metabolism through hepatic cytochrome
P450 enzyme system, as causes of metabolic bone disease due
to increasing metabolism of vitamin D with secondary hypocal-
cemia and hyperparathyroidism (13–15). However, several studies
reported that both enzyme inducing and non-enzyme inducing
AEDs are potentially implicated for the comorbid metabolic bone
disease (10, 12).
Bone mineral density (BMD) tests can identify osteope-
nia/osteoporosis, determine the risk for fractures, and measure
the response to osteoporosis treatment. BMD values depend upon
bone mineral content (BMC) and bone size. The most widely
recognized BMD test is called a dual-energy X-ray absorptiom-
etry (DEXA) (9, 16–18). DEXA is a non-invasive, painless, easy
to use, and with less exposure to irradiation. Biochemical indices
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of bone and mineral metabolism include measurement of blood
concentrations of calcium, phosphorus, vitamin D, parathyroid
hormone (5, 19–23), and bone remodeling markers [e.g., the
receptor activator of nuclear factor-kappa B ligands (RANKL)
and osteoprotegerin (OPG)] (24). Such markers may indirectly
identify patients with bone disease.
The severity of bone disease with AEDs is heterogeneous.
In cases with mild severity, there may be more subtle changes
in bone quality and hypovitaminosis D, hypocalcemia, and
hyperparathyroidism. Cases of intermediate severity may exhibit
characteristic features of osteopenia/osteoporosis. Some patients
with severe bone disease may manifest features of osteomalacic
disorder (5, 13, 25).
The exact pathophysiological mechanisms of secondary or
pathologic bone loss with different AEDs are still uncertain.
However, some mechanisms have been suggested, which include
hepatic enzyme induction with increase in the metabolism of vit-
amin D (13–15), impaired calcium absorption (26), direct effect
of AEDs on bone cells (9), and resistance to parathyroid hor-
mone and inhibition of calcitonin secretion (27). Identification of
exact pathogenic factors involved in development of bone disease
with epilepsy and its medications is of primary importance for
preventive and treatment strategies.
AIM OF THE WORK
This study was aimed to determine the followings in adult patients
with epilepsy and on chronic treatment with AEDs (1) the types
and severity of bone disease, (2) the potential mechanism(s) of
osteoporosis/osteopenia induced by AEDs as data on this sub-
ject are controversial and inconsistent, and (3) the status of
OPG/RANKL system (as markers of bone remodeling) and its
relationship to BMD and related biochemical parameters of bone
disease. The exact role of the OPG/RANKL system and its clinical
magnitude in the pathogenesis of bone disease with epilepsy are
still uncertain.
MATERIALS AND METHODS
This is a comparative cross-sectional case–control study. This
study included 75 adults with age ranged between 20 and 50 years
and duration of illness of 6–25 years. The patients’ seizure types
were diagnosed according to the International League Against
Epilepsy (ILAE) criteria (28). Table 1 showed the demographical
and clinical features of the studied patients. Patients were recruited
from the out-patient epilepsy clinic of the Department of Neurol-
ogy and Psychiatry of Assiut University Hospital, Assiut, Egypt.
All patients were treated with conventional AEDs (CBZ, VPA,
or CBZ+VPA) for at least 6 months before participation in this
study. Forty healthy subjects recruited from the general population
and matched for age- (range: 20–50 years; mean: 30.36± 7.59),
sex-, and socioeconomic status were also included in this study for
statistical comparisons.
Exclusion criteria (for patients and control subjects) included:
(1) a history of an overt medical disorder before the onset of
epilepsy which likely affect bone metabolism [e.g., thyroid (hyper-
thyroidism and hypothyroidism), hepatic, renal hematological,
rheumatologic and gastrointestinal diseases, hypogonadism, and
malabsorption], (2) medications known to affect bone turnover or
Table 1 | Demographical and clinical features of the studied patients.
Age (years) 20–50 (31.90±5.62)
Gender (male/female) 42/33
Body mass index (BMI) (kg/m2) 16–40 (25.89±2.69)
Duration of illness (years) 6–25 (12.65±5.42)
Type of epilepsy
GTC 15 (20%)
Complex partial/partial epilepsy with
secondary generalization
60 (80%)
AED(s) utilized
CBZ 40 (53.33%)
VPA 23 (30.67%)
Polytherapy (CBZ+VPA) 12 (16%)
Dose of AED(s) utilized (mg/day)
CBZ 400–1200 (650.55±289.83)
VPA 750–1400 (1050.85±560.52)
Duration of treatment (years) 6–20 (10.57±3.55)
Serum drug level (µg/ml)
CBZ 4.5–11.0 (8.02±3.05)
VPA 40.86–105.80 (70.65±35.20)
Degree of control on AED(s)
Controlled (seizure free for ≥1 year) 48 (64%)
Uncontrolled 27 (36%)
Values are expressed as mean±SD and number (%).
GTC, generalized tonic-clonic; AEDs, antiepileptic drugs; CBZ, carbamazepine;
VPA, valproate.
can contribute to bone loss (e.g., glucorticoids, bisphosphonates,
thiazides, anticoagulants, and steroids), (3) intake of calcium or
vitamin D supplements, (4) risk factors for osteoporosis [e.g., fam-
ily history of osteoporotic fracture, estrogen deficiency resulting
from early menopause (before age 45 years), either naturally from
surgical removal of the ovaries or as a result of prolonged amen-
orrhea (abnormal absence of menstruation) in younger women,
and (5) overt bone deformities (e.g., osteogenesis imperfecta).
Details of the protocol were approved by the local ethics com-
mittee and all patients gave written informed consent to their
participation.
All patients and healthy control subjects underwent the same
research protocol, which included medical, neurological, and
endocrinological histories and examinations.
Data collection included age, sex, weight, height, and body mass
index (BMI). Seizure variables recorded were: age at onset, dura-
tion of illness, type, frequency, type of utilized AED(s) (monother-
apy or polytherapy), duration of treatment, degree of patients’
control on AED(s), and obvious side effects from medications.
Regarding the degree of control on AEDs, patients were considered
controlled on AEDs, when seizure free for ≥1 year.
BONE MINERAL DENSITY
Bone mineral density was measured using Bone Densitometer,
Dual-Energy, DMS Lexxos DR. BMD was expressed as gram per
square centimeter and as T - and Z -scores. T -score is the differ-
ence in standard deviations between a given bone density value and
peak bone density in the normal reference population. Z -score is
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the age- and sex-adjusted T -score. When a T -score appears as a
negative number (such as –1, –2, or –2.5), it indicates low bone
mass. The greater the negative number, the greater is the risk of
fracture. The World Health Organization (WHO) defines osteo-
porosis as a T -score <−2.5 and osteopenia as a T -score between
−1.0 and −2.49. Subjects with T -scores >−1.0 are considered to
have normal BMD (29).
LABORATORY INVESTIGATIONS
Subjects included in this study were controlled for timing of
blood sampling, which were withdrawn at 8.00–10.00 a.m. after
an overnight fast and were seizure free for at least 72 h (as
any postictal central neurochemical dysfunction, is recognized to
reverse within hours). The samples were centrifuged and serum
aliquot and frozen at −70°C till used for different assays. The
following laboratory tests were done: (a) Standardized, which
included: measurements of complete blood count (CBC) and
serum concentrations of creatinine, liver enzymes, and fasting
blood glucose, and (b) Specific, which included measurements
of serum calcium, magnesium, phosphate, and alkaline phos-
phatase (ALP), which were measured using spectrophotometric
method (Egypt Company for Biotechnology, Cairo, Egypt). Serum
25-hydroxyvitamin D [25(OH)D] was determined using com-
petitive binding protein assay (Immundiagnostik AG, Blenheim,
Germany). Vitamin D deficiency was defined by serum lev-
els of 25OHD <25 nmol/L (10 ng/ml) while insufficiency was
defined as a 25OHD between 25 and 50 nmol/L [10–20 ng/ml
(30)]. Serum levels of OPG and soluble receptor activator of
nuclear factor-kappa B ligand (sRANKL) were measured by
enzyme link immunosorbent assay (ELISA) kits, using reagents
supplied by Bender MedSystems GmbH (Austria, Europe) and
BioVendor Laboratorni medicine (Modrice, Czech Republic).
The sensitivities of the kits were 0.125 pmol/L for OPG and
0.2 pmol/L for sRANKL. Concentrations were assessed in com-
bination with the cross-sectional assessment during clinical eval-
uation and interviewing of patients. The serum levels of AEDs
were measured as part of the investigation in batched assays in
the Therapeutic Drug Monitoring (TDM) laboratory of Assiut
University Hospital, Assiut, Egypt, using Fluorescence Polariza-
tion Immunoassay System of Abbott, TDxFLX apparatus (Abbott
Lab, Wiesbaden, Germany). The approximated reference thera-
peutic serum level of CBZ was 4–10µg/ml and 50–100µg/ml for
VPA (31).
STATISTICAL ANALYSIS
Calculations were done with the statistical package SPSS, ver-
sion 12.0. Data were presented as mean± SD or number and
percentage. The normal distribution of data was confirmed by
calculating skewness and kurtosis before applying standard tests.
For comparison of two groups, the non-parametric test for inde-
pendent variables was used while comparisons of multiple groups
were done using ANOVA and Kruskall–Wallis tests for parametric
and non-parametric variables, respectively. Chi-square test was
used to compare frequency of qualitative variables among dif-
ferent groups. Spearman’s and Pearson’s correlation tests were
used for correlating non-parametric and parametric variables. To
determine the relationship between BMD and markers of bone
turnover, a linear regression analysis was done. For all tests, values
of p< 0.05 were considered statistically significant.
RESULTS
This study included 75 adults with primary epilepsy, with mean age
of 31.90± 5.62 years and duration of illness of 12.65± 5.42 years.
Patients were treated with one or more conventional AED(s) with
nearly three quarter of the patients were on CBZ mono- or poly-
therapy for 10.57± 3.55 years. Nearly, two-thirds of the patients
were controlled on the prescribed AEDs. Tables 2 and 3 showed
the DEXA results of the studied groups and the frequency of
patients with DEXA abnormalities. Compared to control subjects,
patients had significantly lower BMD (p< 0.001; p< 0.0001),
BMC (p< 0.001; p< 0.001), Z -score (p< 0.0001; p< 0.0001),
and T -score (p< 0.0001; p< 0.0001) at the femoral neck and
lumbar spine, respectively. Abnormalities in more than one site
[i.e., femoral neck (unilateral or bilateral) and lumbar spine]
were seen in affected patients. The majority of male patients had
osteoporosis of the femoral neck and lumbar spine while the
majority of females had osteopenia regardless of the type, dose,
or serum level of AEDs [versus 20% (n= 8) for control subjects
with osteopenia in the lumbar spine]. Bone pain (particularly low
Table 2 | Dual-energy X-ray absorption (DEXA) results of the studied
groups.
DEXA results Patients Control subjects
BMD; g/cm2
Femoral neck 0.204–1.132 0.536–0.965
0.740±0.125** 0.897±0.089
L2–L4 0.483–0.983 0.520–0.983
0.665±0.209*** 0.850±0.137
BMC; g
Femoral neck 12.72–52.09 27.99–51.29
33.76±0.17** 48.28±0.25
L2–L4 16.30–67.39 27.38–57.09
39.84±0.26** 47.46±0.06
AREA; cm2
Femoral neck 22.46–76.17 38.77–64.98
39.96±0.14** 49.75±0.45
L2–L4 30.76–71.27 32.77–67.78
47.37±0.08** 37.33±0.25
Z -SCORE
Femoral neck −7.9 to 0.2 −2.2 to 2.0
−3.9±2.6*** 1.5±0.6
L2–L4 −6.6 to 1.9 −1.5 to 2.0
−4.5±2.1*** 1.2±0.3
T -SCORE
Femoral neck −7.0 to 0.1 −0.6 to 3.0
−5.6±1.0*** 2.44±1.1
L2–L4 −6.6 to −2.0 −0.5–3.0
−4.43±0.2*** 1.5±0.8
Data are expressed as range and mean±SD.
BMD, bone mineral density; BMC, bone mineral content.
**Significance: 0.001; ***significance: 0.0001.
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Table 3 |The frequency of patients with Dual-energy X-ray absorption
(DEXA) abnormalities.
Bone mineral
density (BMD)
Femoral neck (n=75) Lumbar spine
(L2–L4) (n=75)
Unilateral Bilateral
Osteopenia
(T -score −1.0 to −2.49)
18 (24%) 4 (5.33%) 10 (13.33%)
Males 10 (55.56%) 3 (75%) 3 (30%)
Females 8 (44.44%) 1 (25%) 7 (70%)
Osteoporosis
(T -score <−2.5)
13 (17.33%) 3 (4%) 54 (72%)
Males 9 (69.23%) 3 (100%) 33 (61.11%)
Females 4 (30.77%) 0 21 (38.89%)
back pain) was reported in 45 patients (33.75%) particularly in
female (n= 36, 80%). Twenty patients (15%) had history of limb
fracture (males= 13, 65%; females= 7, 35%) before participation
in this study. Tables 4 and 5 showed the laboratory results of
the studied groups and the frequency of patients with abnormal
biochemical parameters. Compared to control subjects, patients
had significantly lower serum calcium (p< 0.0001), 25(OH)D
(p< 0.0001), and OPG (p< 0.001) and higher ALP (p< 0.001),
sRANKL (p< 0.0001) levels, and sRANKL/OPG (p< 0.0001).
Nearly, 52% of the patients had hypocalcemia [versus 25% or
n= 12 control subjects], 93% of the patients had vitamin D defi-
ciency/insufficiency [versus 30% or n= 12 control subjects with
vitamin D insufficiency], and 31% had high levels of sRANKL
and 49% had low levels of OPG. No significant differences were
identified between the levels of different laboratory and DEXA
results in relation to the age, gender, weight, type, dose, or serum
levels of AEDs, mono- versus polytherapy and the degree of con-
trol on AEDs. Correlations between demographical-, clinical-,
laboratory-, and DEXA parameters showed that in patients with
epilepsy (Table 6): (1) duration of illness and BMD at the femoral
neck and lumbar spine respectively, (2) the duration of treatment
with AEDs were correlated with BMD at the femoral neck and
lumbar spine, respectively, levels of calcium, 25(OH)D, sRANKL,
and OPG, (3) BMD at the femoral neck and lumbar spine and
serum levels of 25(OH)D, sRANKL, and OPG, (4) levels of cal-
cium and 25(OH)D, (5) sRANKL and OPG. In linear regression
analysis and after adjusting for gender, age, weight, duration of
therapy, and number of AEDs, we observed an association between
BMD, 25(OH)D (partial R2= 1.5, p= 0.04), and sRANKL (partial
R2= 1.7%, p= 0.03) concentrations.
DISCUSSION
Although the knowledge regarding disease- and AEDs-related
bone abnormalities are rapidly increasing; however, data regard-
ing the mechanisms of bone loss in patients with epilepsy are
not clearly understood. In this study, the potential relationships
between the BMD findings in a group of ambulatory adults with
epilepsy and treated with AEDs and markers of bone remodel-
ing, which include calcium, 25(OH)D, ALP, and OPG/RANKL
Table 4 | Laboratory results of the studied groups.
Laboratory variable Patients Controls
Calcium (mg/dL) 5.50–11.00 8.00–10.22
6.86±1.06*** 9.35±1.11
Magnesium (mg/dL) 1.30–5.30 1.60–2.69
3.54±0.07 4.04±0.52
Phosphorus (mg/dL) 2.21–7.26 2.60–5.56
4.09±1.01 3.32±0.72
ALP (IU/L) 236.76–965.76 287.04–665.90
703.54±254.89** 468.75±203.50
25(OH)D (nmol/L) 12.00–55.00 70.00–112.00
25.67±8.09*** 88.70± 5.94
sRANKL (pmol/L) 4.03–16.49 0.49–5.51
10.34±3.34*** 2.46±1.17
OPG (pmol/L) 0.37–3.73 2.71–4.41
2.09±0.78** 3.96±0.59
sRANKL/OPG ratio 1.08–37.22 0.15–2.03
6.55±0.13*** 0.73±0.43
Data are expressed as range and mean±SD.
ALP, alkaline phosphatase; 25(OH)D, 25-hydroxyvitamin D; sRANKL, soluble
receptor activator of nuclear factor-kappa B ligand; OPG, osteoprotegerin.
**Significance: 0.001; ***significance: 0.0001.
Table 5 |The frequency of patients with abnormal biochemical
parameters.
Laboratory variable Patients (n=75)
Calcium 39 (52%)
Magnesium 8 (10.67%)
Phosphorus 4 (5.33%)
ALP 32 (42.67%)
25(OH)D
Vitamin D deficiency (<25 nmol/L) 50 (66.67%)
Vitamin D insufficiency (25–50 nmol/L) 20 (26.67%)
sRANKL 23 (30.67%)
OPG 29 (38.67%)
ALP, alkaline phosphatase; 25(OH)D, 25-hydroxyvitamin D; sRANKL, soluble
receptor activator of nuclear factor-kappa B ligand; OPG, osteoprotegerin.
systems were discussed. The results of this study showed that
in ambulatory adults with epilepsy and on chronic treatment
with AEDs, there is an increased risk of (1) bone loss (osteope-
nia/osteoporosis) and fracture, (2) hypocalcemia (52%) and
25(OH)D deficiency/insufficiency, (3) increased bone turnover
as indicated by lower serum levels of OPG and higher levels
of sRANKL and sRANKL/OPG ratio (markers of bone remod-
eling), and (4) metabolic bone compromise with prolongation
of the duration of treatment with AEDs due to disturbed min-
eral metabolism associated with compromise of bone remodeling
with accelerated bone turnover. These changes occur regardless of
patients’ age, gender, weight, type, dose, or serum levels of AEDs,
number of utilized AEDs, and the degree of control on AEDs, but
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Table 6 | Correlations between demographic-, clinical-, laboratory- and DEXA parameters.
Variables Duration of illness Duration of treatment Calcium 25(OH)D sRANKL OPG
BMD
Femoral neck −0.360 −0.505 – 0.476 −0.478 0.480
0.043 <0.001 – 0.042 0.005 0.006
L2–l4 −0.432 −0.301 – 0.360 −0.360 0.330
0.010 0.012 – 0.010 0.010 0.010
Calcium – −0.455 – 0.386 – –
– 0.005 – 0.005 – –
25(OH)D – −0.655 0.386 – – –
– <0.001 0.005 – – –
sRANKL – 0.387 – – – −0.725
– 0.007 – – – <0.001
OPG – −0.525 – – −0.725 –
– <0.001 – – <0.001 –
BMD, bone mineral density; 25(OH)D, 25-hydroxyvitamin D; sRANKL, soluble receptor activator of nuclear factor-kappa B ligand; OPG, osteoprotegerin.
BMD loss was also associated with prolongation of the disease
duration which also indicated prolonged duration of treatment.
First, the findings of this study showed increased markers of
bone loss as evidenced by lower BMD, BMC, Z -score, and T -
score at the femoral neck and lumbar spine regardless of the
type, dose, or serum level of the utilized AED. Osteoporosis of
the femoral neck was reported in 21.33% while that of the lumbar
spine was reported in 72%. Osteopenia of the femoral neck was
reported in 29.33% while that of the lumbar spine was reported
in 13.33%. No significant differences in DEXA results were iden-
tified between patients on CBZ, VPA, or polytherapy. Bone mass
changes reported in the literature vary greatly for patients under-
going treatment with AEDs and ranged between 13 and 75%.
However, both enzyme inducing and non-enzyme inducing AEDs
are potentially implicated for bone mass loss with epilepsy (10,
12–15, 20). The majority of male patients had osteoporosis of
the femoral neck and lumbar spine while the majority of females
had osteopenia. The variations between the results of different
studies may depend on the type of AEDs used, and the AED
blood level required for effective treatment. Other factors may
include the length of time of treatment, the existence of associated
pathologies, the age and sex of the patients, their level of physi-
cal activity, and where and how the measurements are made. We
reported history of fracture in 15%, which was predominant in
males (7, 32). It has been reported that gender plays a major role
in the pathogenesis of fractures. In accordance, Cummings et al.
(33) reported that fractures commonly occurred in males aged
<40 years (between 30 and 49) and then rapidly declined while
the peak rate occurred 20 years later (between age 50 and 59 years)
in females, and declined subsequently.
Second, the findings of this study showed that biochemi-
cal abnormalities of bone-related mineral metabolism included
hypocalcemia (52%) and hypovitaminosis D (93.33%). 25(OH)D
levels were positively correlated with calcium levels but nega-
tively correlated with BMD. 25(OH)D deficiency/insufficiency was
reported irrespective to the type of AED (17). Hypovitaminosis D
was previously reported in 50% of ambulatory patients on AEDs.
The other common laboratory abnormalities described in relation
to AED are elevated levels of ALP and hyperparathyroidiam (5, 13,
17, 19, 20, 34). It has been suggested that hepatic induction of
cytochrome P450 enzymes by enzyme inducing AEDs (e.g., phe-
nobarbital, phenytoin, and CBZ) increases the metabolism and
clearance of vitamin D with secondary hypocalcemia and hyper-
parathyroidism (13–15). The mechanism of disturbed mineral
metabolism due to VPA is not completely understood. VPA may
cause renal tubular dysfunction, which could indirectly influence
bone and mineral metabolism with increased urinary loss of cal-
cium and phosphorus. In support, VPA has been associated with
reversible Fanconi syndrome (35). It is known that approximately
99% of calcium in the body is stored in the skeleton. Calcium
is stored in or removed from the skeleton to regulate serum cal-
cium levels. 25(OH)D is the major circulating form of vitamin
D. 25[OH]D is biologically inert and transported to the kidney,
where renal 1a-hydroxylase converts 25(OH)D to 1,25(OH)2D.
1,25(OH)2D is an important regulator of serum calcium con-
centration. 1,25(OH)2D directly enhances the entry of calcium
through the plasma membrane into intestinal absorption cells
and transfers calcium across the basolateral membrane into the
circulation to maintain calcium homeostasis. 1,25(OH)2D pro-
motes mineralization of osteoid and, with appropriate levels of
calcium and phosphorus, induces deposition of calcium hydrox-
yapatite into the bone matrix (36). Controversial results reported
lack of any correlation between vitamin D and BMD in patients
with epilepsy in some studies (4, 37). Some suggested that AEDs
may inhibit vitamin D-mediated calcium absorption (26). Filardi
et al. (38) reported that adults who were on chronic anticonvul-
sant therapy and who lived in low latitude regions had normal
bone mineral density as well as vitamin D serum level. Mattson
and Gidal (14) reported low BMD irrespective of vitamin D levels.
Verrotti et al. (22) reported that VPA doses do not seem to change
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bone turnover in adult epileptic patients. This could be explained
by vitamin D-independent pathways such as impaired calcium
absorption (26), resistance to parathyroid hormone and inhibi-
tion of calcitonin secretion (27), direct effects of AEDs on bone
cells (9), hyperparathyroidism and calcitonin deficiency (39).
Third, this study showed reduced levels of OPG and higher lev-
els of sRANKL and sRANKL/OPG ratio in patients with epilepsy,
the duration of treatment with AEDs were positively correlated
with sRANKs and negatively correlated with OPG, BMD at the
femoral neck, and lumbar spine and serum levels of sRANKL and
OPG and in linear regression analysis and after adjusting for gen-
der, age, weight, duration of therapy, and number of AEDs, we
observed an association between BMD, 25(OH)D, and sRANKL
concentrations.
Bone is a complex dynamic tissue. It undergoes remodeling,
a continuing process of bone resorption and formation in dis-
crete areas throughout the skeleton. BMD represents a coordinated
action or the balance between bone resorption or the bone-
depleting action of osteoclasts and the bone-formative action of
osteoblasts (bone remodeling). Osteoclast and osteoblast (main
bone cells) dynamics, body weight, exercise, vitamin D, calcium,
and phosphorous homeostasis as well as connective tissue arrange-
ments can alter bone structure and architecture. Several hormones,
polypeptides, cytokines, growth factors, nutrients, minerals, and
essential cofactors, regulate bone remodeling. The active metabo-
lite of vitamin D [1,25(OH)2D] and adequate amounts of cal-
cium and phosphorus are required for bone formation (40).
Bone remodeling is intimately related to changes in expression
of members of tumor necrosis factor (TNF) receptor superfam-
ily on bone marrow stromal cells [e.g., the macrophage colony-
stimulating factor (M-CSF); the receptor activator of nuclear
factor-kappa B ligands (RANKL), RANK and OPG] and vari-
ous cytokines and calciotropic hormones (41). RANKL binds the
RANK receptor on osteoclast precursors and induces the for-
mation of osteoclasts by a special signaling pathway (42, 43). A
soluble form of RANKL (sRANKL) is released from its membrane
bound state by metalloproteinases. OPG blocks the RANKL–
RANK interaction by binding to and neutralizing both soluble
and cell-bound forms of RANKL thus inhibits osteoclast dif-
ferentiation and activation (44). It is the balance between the
expression of RANKL and OPG that determines the extent of
bone resorption. It has been suggested that in patients with
epilepsy and in order to improve calcium absorption when the
25-OH Vitamin D level is low, 1,25OHD is increased, a con-
version step mediated by parathormone. Elevation of the active
metabolite of vitamin D, 1,25OHD, can stimulate bone resorption
through the receptor-activated NF-KB ligand (RANKL), promot-
ing maturation of osteoclasts (24). In support, bone biopsies from
patients with epilepsy revealed diminished volume of trabecu-
lar bone and increased amount of osteoclastic resorptive activity
and osteoid in 10 and 40% of patients receiving long-term AED
therapy (37).
Despite the strength of this study, it has some limitations: (1)
the recruitment of the study group from a tertiary care center
with more severe cases and this explains the high percentage of
observed bone loss evidence by DEXA and the biochemically
related abnormalities, (2) because of the cross-sectional nature
of the present study, it was not possible to know temporal rela-
tionship between bone loss to the use of AEDs. However, such
limitations could only be overcome through a longitudinal and
multi-center study design.
CONCLUSION
Ambulatory adults with epilepsy and chronic treatment with AEDs
are at greater risk of metabolic osteopathy as evidenced by osteope-
nia/osteoporosis, fracture, hypocalcemia, and hypovitaminosis D.
The metabolic bone loss and mineral abnormalities are associated
with accelerated bone turnover as evidenced by higher levels of
sRANKL and sRANKL/OPG ratio and lower levels of OPG (mark-
ers of bone remodeling). Thus, patients receiving long-term AED
have to be monitored for indices of bone health, including BMD
and vitamin D status and to be provided with proper preventive
and treatment strategies.
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